Free Trial
NASDAQ:BHST

BioHarvest Sciences (BHST) Stock Price, News & Analysis

BioHarvest Sciences logo
$6.27 -0.08 (-1.26%)
As of 05/30/2025 03:58 PM Eastern

About BioHarvest Sciences Stock (NASDAQ:BHST)

Key Stats

Today's Range
$6.25
$6.35
50-Day Range
$5.25
$6.75
52-Week Range
$6.25
$7.38
Volume
8,890 shs
Average Volume
17,070 shs
Market Capitalization
$102.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.67
Consensus Rating
Buy

Company Overview

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Receive BHST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioHarvest Sciences and its competitors with MarketBeat's FREE daily newsletter.

BHST Stock News Headlines

BioHarvest enters fragrance industry with AI edge - ICYMI
Big Oil’s big pivot
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.
HC Wainwright Has Pessimistic Outlook of BHST Q2 Earnings
BioHarvest Sciences Q1 revenue jumps on VINIA growth
See More Headlines

BHST Stock Analysis - Frequently Asked Questions

BioHarvest Sciences' stock was trading at $6.18 at the beginning of the year. Since then, BHST stock has increased by 1.5% and is now trading at $6.27.
View the best growth stocks for 2025 here
.

BioHarvest Sciences Inc. (NASDAQ:BHST) issued its quarterly earnings data on Thursday, May, 15th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. The firm had revenue of $7.64 million for the quarter, compared to analyst estimates of $8.93 million.
Read the conference call transcript
.

Top institutional investors of BioHarvest Sciences include Magnus Financial Group LLC (0.44%) and True North Advisors LLC (0.27%).

Shares of BHST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/15/2025
Today
6/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BHST
Previous Symbol
NASDAQ:BHST
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$13.67
High Stock Price Target
$15.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+118.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.56 million
Pretax Margin
-76.65%

Debt

Sales & Book Value

Annual Sales
$27.70 million
Price / Cash Flow
N/A
Book Value
($1.08) per share
Price / Book
-5.81

Miscellaneous

Free Float
N/A
Market Cap
$102.98 million
Optionable
N/A
Beta
0.80
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:BHST) was last updated on 6/2/2025 by MarketBeat.com Staff
From Our Partners